Progress Pharma SA
The score of Progress Pharma shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity -52 % Total assets -49 %
Accounts of the company itself (not consolidated).
The full file covers 10 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Progress Pharma's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 05 Jun 2026
- Year ended 31 Dec 2024filed on 16 May 2025
- Year ended 31 Dec 2023filed on 27 Jun 2024
- Year ended 31 Dec 2022filed on 20 Jun 2023
- Year ended 31 Dec 2021filed on 04 Jul 2022
Progress Pharma's financial analysis
- Solvency94.4%sector median: 61.7%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Progress Pharma
Progress Pharma's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0536.258.560
- VAT number
- BE0536258560
- Peppol
- Registered · 0208:0536258560 · as of 02 Nov 2026
- Legal form
- SA
- Incorporated
- 27 Jun 2013
- Registered office
- 2350 Vosselaar
- Latest accounts
- 2025 · filed on 05 Jun 2026
- Activity
- Research and experimental development on other natural sciences and engineering (NACE 72109)
Progress Pharma (SA) has been based in Vosselaar since 2013, active in: research and experimental development on other natural sciences and engineering. For 2025, it reports a net loss of 5,479 € and equity of 47,137 €; its revenue is not published. Its solvency stands at 94.4%, above the median of its sector (61.7%).
Companies similar to Progress Pharma
Companies in the same business, of comparable size and area, outside its group.
- Spray Ventures Research and experimental development on natural sciences and engineering Deinze · balance sheet 27,331 €
- Phytex Research and experimental development on natural sciences and engineering Court-Saint-Étienne · balance sheet 42,587 €
- Belgium Volt Research and experimental development on natural sciences and engineering Auderghem · balance sheet 41,754 €
- Atelier Energie Other business support service activities n.e.c. Libramont-Chevigny · balance sheet 20,566 €
- MSI-Dfat EU Research and experimental development on natural sciences and engineering Jodoigne · balance sheet €1.08m
- Bloonics Labs Research and experimental development on natural sciences and engineering Leuven · balance sheet 65,778 €
- Palmir Research and experimental development on natural sciences and engineering Wommelgem · balance sheet 4 €
- Innovative Material Processing Technologies Research and experimental development on natural sciences and engineering Liège · balance sheet 10,393 €
Frequently asked questions about Progress Pharma
What is the revenue of Progress Pharma?
Progress Pharma files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Progress Pharma?
In Belgium, the VAT number is the company number prefixed with BE: BE0536258560 for Progress Pharma, if the company is VAT-registered. Its company number (CBE) is 0536.258.560.
Where is the registered office of Progress Pharma?
According to the CBE register, the registered office of Progress Pharma is in 2350 Vosselaar.
What is the equity of Progress Pharma?
At the close of the 2025 financial year, the equity of Progress Pharma amounts to 47,137 €, a solvency of 94.4% of total assets.
Who manages Progress Pharma?
The register lists 10 active mandates at Progress Pharma. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Progress Pharma
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →